Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings
- PMID: 24943062
- DOI: 10.1097/FTD.0000000000000108
Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings
Abstract
Coadministration of antituberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis (TB) is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and many antiretroviral drugs is complicated by pharmacokinetic drug-drug interactions. Rifampicin is a very potent enzyme inducer, which can result in subtherapeutic antiretroviral drug concentrations. In addition, TB drugs and antiretroviral drugs have additive (pharmacodynamic) interactions as reflected in overlapping adverse effect profiles. This review provides an overview of the pharmacological interactions between rifampicin-based TB treatment and antiretroviral drugs in adults living in resource-limited settings. Major progress has been made to evaluate the interactions between TB drugs and antiretroviral therapy; however, burning questions remain concerning nevirapine and efavirenz effectiveness during rifampicin-based TB treatment, treatment options for TB-HIV-coinfected patients with nonnucleoside reverse transcriptase inhibitor resistance or intolerance, and exact treatment or dosing schedules for vulnerable patients including children and pregnant women. The current research priorities can be addressed by maximizing the use of already existing data, creating new data by conducting clinical trials and prospective observational studies and to engage a lobby to make currently unavailable drugs available to those most in need.
Similar articles
-
Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.Antivir Ther. 2009;14(8):1039-43. doi: 10.3851/IMP1455. Antivir Ther. 2009. PMID: 20032533 Review.
-
Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.J Antimicrob Chemother. 2007 Apr;59(4):690-7. doi: 10.1093/jac/dkl552. Epub 2007 Feb 16. J Antimicrob Chemother. 2007. PMID: 17307771
-
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5. Antivir Ther. 2013. PMID: 23043067 Clinical Trial.
-
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.JAMA. 2008 Aug 6;300(5):530-9. doi: 10.1001/jama.300.5.530. JAMA. 2008. PMID: 18677025
-
Tuberculosis and HIV co-infection: a practical therapeutic approach.Drugs. 2006;66(18):2299-308. doi: 10.2165/00003495-200666180-00003. Drugs. 2006. PMID: 17181373 Review.
Cited by
-
Four months of rifampicin monotherapy for latent tuberculosis infection in children.Clin Exp Pediatr. 2022 May;65(5):214-221. doi: 10.3345/cep.2021.01186. Epub 2021 Oct 29. Clin Exp Pediatr. 2022. PMID: 34727494 Free PMC article.
-
Rifampicin for COVID-19.World J Virol. 2022 Mar 25;11(2):90-97. doi: 10.5501/wjv.v11.i2.90. World J Virol. 2022. PMID: 35433334 Free PMC article. Review.
-
Can we involve pharmacists as direct service providers for people with tuberculosis? A narrative review of current evidence.Explor Res Clin Soc Pharm. 2025 May 18;19:100613. doi: 10.1016/j.rcsop.2025.100613. eCollection 2025 Sep. Explor Res Clin Soc Pharm. 2025. PMID: 40502458 Free PMC article. Review.
-
Evaluation of the impact of rifampicin on the plasma concentration of linezolid in tuberculosis co-infected patients.Front Pharmacol. 2023 Nov 7;14:1260535. doi: 10.3389/fphar.2023.1260535. eCollection 2023. Front Pharmacol. 2023. PMID: 38026932 Free PMC article.
-
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study.Lancet HIV. 2025 Apr;12(4):e273-e282. doi: 10.1016/S2352-3018(24)00312-6. Epub 2025 Feb 26. Lancet HIV. 2025. PMID: 40023169 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical